From the Wires
Onyx Pharmaceuticals Announces Public Offering of Common Stock
By: Marketwired .
Jan. 15, 2013 05:14 PM
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 01/15/13 -- Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) today announced an underwritten public offering of 4,400,000 shares of its common stock. Onyx has also granted the underwriters a 30-day option to purchase up to an additional 660,000 shares of common stock offered in the public offering to cover overallotments, if any. The offering is expected to close on or about January 22, 2013, subject to customary closing conditions. Onyx intends to use the net proceeds from this offering to fund its clinical development programs, research and development activities, and sales and marketing activities to commercialize Kyprolis around the world, and for general corporate purposes, including working capital.
BofA Merrill Lynch and Barclays are acting as joint book-running managers for this offering.
A registration statement relating to the shares described above was previously filed with and has become effective by rule of the Securities and Exchange Commission (the "SEC"). A preliminary prospectus supplement relating to the offering will be filed with the SEC and will be available on the SEC's website at http://www.sec.gov. Copies of the preliminary prospectus supplement and related prospectus, when available, may be obtained from BofA Merrill Lynch, 222 Broadway, New York, NY 10038, attention: Prospectus Department, or e-mail firstname.lastname@example.org, or Barclays, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 (telephone number 888-603-5847), or email Barclaysprospectus@broadridge.com.
This news release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Onyx Pharmaceuticals, Inc.
SOA World Latest Stories
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
SYS-CON Featured Whitepapers
Most Read This Week